VEGFA and neoplasm: The humanized anti-VEGF monoclonal antibody bevacizumab (Avastin®) is the first anti-angiogenic agent approved by the US Food and Drug Administration as a treatment for different types of tumor in combination with chemotherapy [11,12,13].